A certificate of analysis (CoA) for BPC-157 is a laboratory document describing one batch of material at one point in time: what the molecule is, how much of the sample is that molecule, how much peptide the vial actually contains, and which salt form was supplied. It is a composition record, not a safety or performance record. BPC-157 is sold as a research chemical for research use only, and the only thing a buyer can verify from a distance is the quality of the paperwork behind it. This guide walks through the fields a complete BPC-157 report shows, what is typical in vendor CoAs for this particular peptide, and which absences are meaningful.
What does third-party testing actually mean for a BPC-157 batch?
Third-party testing means a laboratory with no commercial interest in the sale analysed a defined batch and issued the result under its own name. That is different from in-house quality control, and different again from a supplier simply repeating a figure printed on a bulk manufacturer's spec sheet. Three conditions separate a genuine third-party report from a decorative one: the lab is named (independent testing labs such as Janoshik or MZ Biolabs, rather than the phrase tested by an accredited US lab with no identity), the report is batch-level rather than generic, and the result is verifiable at the source, usually through a code or QR that resolves on the laboratory's own domain instead of a PDF hosted only by the seller. ISO/IEC 17025 is the international accreditation standard for the technical competence of testing laboratories, so accreditation is a stronger signal than its absence. Transparency is a documentary property, not a marketing claim. Our ten weighted scoring criteria are built around exactly these conditions.
What does each test on a BPC-157 CoA answer?
Buyers often treat a CoA as one number. It is really several independent questions, each answered by a different method. Identity and purity answer different questions, and net content answers a third.
| Field | Method | Question it answers |
|---|---|---|
| Identity | Mass spectrometry (MS) or liquid chromatography mass spectrometry (LC-MS) | Is this molecule BPC-157 and not another compound? |
| Purity | High-performance liquid chromatography (HPLC) | What share of the detected material is the target peak? |
| Net peptide content | Amino acid analysis (AAA) or nitrogen determination | How much actual peptide is in the vial, excluding water, salts and counter-ions? |
| Traceability | Batch or lot number, date of analysis, verification code | Does this document describe the vial in my hand? |
What should the identity section of a BPC-157 CoA show?
Identity is the field most often skipped, and the one that matters most. HPLC can report a beautifully clean single peak for a substance that is not the peptide you ordered: a sample can be 99% pure and still be the wrong molecule. Mass spectrometry is what rules that out, by measuring molecular mass and comparing it with the mass expected for the claimed sequence. BPC-157 is a pentadecapeptide, a chain of 15 amino acids, so its theoretical mass is fixed and publicly documented. A complete report therefore prints the expected mass alongside the observed mass, letting you compare the two yourself rather than trusting a conclusion. Stronger reports include the mass spectrum itself. Where only a word such as conforms appears with no figures and no spectrum, the identity claim is an assertion, not evidence. The distinction between the two methods is covered in detail in our guide to purity versus identity testing.
What does the HPLC purity figure really tell you?
HPLC separates a sample into peaks and reports the target peak as a percentage of total peak area, for example 99.0%. Two points follow from that definition. First, it is a relative measure: it describes the proportion of what the detector saw, so anything the method does not detect or does not resolve is invisible to the number. Second, the chromatogram, the plotted trace with its baseline, retention time and neighbouring impurity peaks, is the actual evidence. A bare percentage with no chromatogram attached is a weak signal, because nothing in it can be checked. On a credible BPC-157 report you can see where the main peak sits, how clean the baseline is, and whether small related-substance peaks sit close to the target. Read the chromatogram, not just the number. Rounded marketing figures such as over 99% pure with no trace, no method conditions and no lab name carry no verifiable information at all.
Why is net peptide content a separate number?
Purity and net content are frequently confused, and for lyophilised peptides the gap between them is real. Purity by HPLC describes the composition of the peptide fraction. Net peptide content, determined by amino acid analysis or nitrogen determination, describes how much of the powder in the vial is peptide at all, after water, residual solvents, salts and counter-ions are accounted for. Material can be highly pure by area and still represent noticeably less peptide per vial than the label suggests, because freeze-dried powder holds moisture and salt. This is why the figure printed on the vial, often given in milligrams, is a label claim rather than a measurement unless a CoA supports it. A BPC-157 report that states purity but says nothing about net content or mass of fill leaves the quantity question open. Our anatomy of a peptide CoA sets out where each of these fields normally appears.
Why must the CoA state whether the salt form is acetate or arginate?
Peptides are isolated as salts, so every vial contains a counter-ion. BPC-157 is commonly supplied as an acetate salt, and some suppliers describe an arginate form, meaning an arginine counter-ion. Trifluoroacetate (TFA) can also remain from purification unless a salt exchange was performed. This is not a cosmetic detail: the counter-ion contributes to the total mass of the powder, so two vials of identical stated weight and identical HPLC purity can hold different quantities of peptide depending on the salt supplied. Mass spectrometry does not settle the question either, because it measures the peptide, while the counter-ion is associated rather than covalently bound. The salt form must therefore be declared in writing on the CoA or the label, and ideally reconciled with net peptide content. When a product is marketed as an arginate form but the documentation is silent on salt identity and residual TFA, the paperwork does not support the claim on the front of the box.
Which batch and date details make the document verifiable?
A CoA describes a batch, not a brand. That makes traceability a structural requirement rather than a formality. Check four fields. The batch or lot number on the certificate should match the number printed on the vial you received, character for character. The date of analysis should be present, because results describe material at a point in time and a two-year-old certificate says nothing about a recently produced batch. The product identity and stated fill weight should match the label. And a verification mechanism, a code, QR or portal reference, should resolve on the testing laboratory's own domain so the result can be confirmed independently of the seller. One generic certificate reused across an entire catalogue, with no lot number anywhere, cannot be tied to any physical vial and therefore proves nothing about yours.
What is typical in BPC-157 vendor CoAs, and what is usually absent?
In practice, most BPC-157 certificates in circulation report HPLC purity as a percentage, and a growing share include an MS identity result. Attached chromatograms and mass spectra are less consistent. Net peptide content and an explicit salt-form declaration are the fields most often missing, even on otherwise careful reports. Microbiological data is a different category: a standard peptide purity and identity CoA usually does not include sterility or endotoxin testing, and that absence is normal rather than suspicious. Endotoxins, which are bacterial lipopolysaccharides, are measured by the LAL (Limulus Amebocyte Lysate) assay and reported in EU/mg or EU/mL under USP chapter 85, while sterility, the detection of viable microorganisms, is a separate test under USP chapter 71. Passing one does not imply the other, and the silence of a purity CoA on both must never be read as a sterility guarantee.
Which gaps on a BPC-157 CoA are genuine red flags?
Some omissions are routine. Others break the chain of evidence entirely. The following patterns mean a document cannot be verified, whatever figure it displays:
- No laboratory name, or a lab that cannot be shown to exist.
- A purity percentage with no chromatogram or spectrum behind it.
- No batch or lot number, or a number that does not match the vial.
- No date of analysis.
- One generic certificate reused across every product in the catalogue.
- No statement of salt form (acetate, arginate or residual TFA) anywhere in the documentation.
- CoAs available only by email on request, after purchase.
- A verification code, QR or portal that leads nowhere.
To see how these criteria are weighted and applied consistently across suppliers, read our scoring methodology and then compare results on the vendor transparency scoreboard.
This guide is educational and covers laboratory documentation only. BPC-157 is a research chemical for research use only. Nothing here is medical advice, and no information is provided on dosing, administration, or any use in humans or animals. A purity and identity CoA describes composition at a point in time, not safety, legality or suitability for any purpose.